Rapid Dose Therapeutics Advances Cannabinoid Research and Clinical Evaluation of QuickStrip(TM) Platform

Executive Summary

• Rapid Dose Therapeutics provided an update on its cannabinoid research program funded by the NFL and a clinical study evaluating CBD bioavailability via its QuickStrip™ oral thin‑film platform.
• Over 60 % of raw data have been extracted for participants enrolled to date, with remaining enrollment expected to continue in Q2 2026.
• Stability studies on the investigational CBD QuickStrip™ product are ongoing, supporting further validation of the delivery technology across pharmaceutical and wellness applications.

Key Details

• Independent research led by Dr. Patrick Neary (University of Regina) and Dr. Jane Alcorn (University of Saskatchewan) is examining naturally produced cannabinoids for pain management and neuroprotection in concussion‑related sports injuries; the program is funded by an NFL grant.
• A separate clinical arm, initiated in Q2 2024, compares the bioavailability of cannabidiol (CBD) delivered via QuickStrip™ oral thin film versus traditional oral dosage forms, measuring absorption efficiency and residence time.
• Raw data have been extracted for >60 % of enrolled participants; enrollment of remaining subjects is slated to continue through Q2 2026.
• Real‑time and accelerated stability studies of the investigational CBD QuickStrip™ product are in progress.
• The Company believes these initiatives further validate QuickStrip™’s potential for rapid, discreet, and efficient delivery across pharmaceutical and consumer wellness markets.

Notable Quotes

“The study is progressing as planned, with raw data extracted for over 60 % of enrolled participants to date… we can determine whether the strips deliver CBD more efficiently than the standard oral form,” – Dr. Jane Alcorn, College of Pharmacy & Nutrition, University of Saskatchewan.